Compare
PMGC Holdings Inc. vs Vaccinex, Inc. vs Yarrow Bioscience, Inc. vs Silence Therapeutics plc
| Latest fiscal year | PMGC Holdings Inc. ELAB | Vaccinex, Inc. VCNXLast annual report: year ended 2024-12-31 | Yarrow Bioscience, Inc. YARW | Silence Therapeutics plc SLN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2024-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $590.1K | $601.0K | $570.0K | $559.0K |
| Revenue growth (YoY) | n/a | +5.4% | +13.8% | -98.7% |
| Gross margin | 31.4% | n/a | n/a | 61.5% |
| Operating margin | n/a | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$7.75M | -$18.63M | -$26.48M | -$88.61M |
| EPS (Diluted) | n/a | -$8.88 | -$0.62 | -$0.63 |
| Operating cash flow | -$5.93M | -$16.19M | -$33.12M | -$62.27M |
| Free cash flow | -$6.38M | -$16.21M | -$33.12M | -$62.33M |
| Cash & equivalents | n/a | $1.11M | $24.03M | $11.28M |
| Total assets | $12.87M | $2.60M | $30.16M | $131.44M |
| Total liabilities | $5.03M | $5.08M | $2.40M | $69.14M |
| Shareholders' equity | $7.84M | -$2.49M | $27.77M | $62.30M |
| Return on year-end equity | -98.9% | n/a | -95.4% | -142.2% |
| Shares outstanding | 80.7K | 2.68M | 33.32M | 141.70M |
Revenue, most recent five fiscal years
| Fiscal year | PMGC Holdings Inc. | Vaccinex, Inc. | Yarrow Bioscience, Inc. | Silence Therapeutics plc |
|---|---|---|---|---|
| Latest | $590.1K Ended 2025-12-31 | $601.0K Ended 2024-12-31 | $570.0K Ended 2025-12-31 | $559.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $570.0K Ended 2023-12-31 | $501.0K Ended 2024-12-31 | $43.26M Ended 2024-12-31 |
| 2 years earlier | $1.71M Ended 2023-12-31 | $275.0K Ended 2022-12-31 | $424.0K Ended 2023-12-31 | $31.64M Ended 2023-12-31 |
| 3 years earlier | $766.3K Ended 2022-12-31 | $900.0K Ended 2021-12-31 | $477.0K Ended 2022-12-31 | $21.66M Ended 2022-12-31 |
| 4 years earlier | n/a | $625.0K Ended 2020-12-31 | $931.0K Ended 2021-12-31 | n/a |